What is the recommended hormone replacement therapy regimen and contraindications for a 45‑year‑old postmenopausal woman with moderate‑to‑severe vasomotor symptoms and an intact uterus?

Hormone Replacement Therapy for Postmenopausal Vasomotor Symptoms

For a 45-year-old postmenopausal woman with moderate-to-severe vasomotor symptoms and an intact uterus, prescribe combined estrogen plus progestogen therapy (EPT) using the lowest effective dose, provided she has no contraindications. 1

Recommended Regimen

Estrogen plus progestogen is mandatory because unopposed estrogen in women with an intact uterus increases endometrial cancer risk 1. The specific regimen should be:

• Estrogen component: Start with low-dose estrogen (oral or transdermal)
• Progestogen component: Add progestogen for 10-14 days per month (cyclic) OR daily (continuous) 2
• Route consideration: Transdermal estradiol is preferred over oral formulations to avoid hepatic first-pass effects and potentially reduce thromboembolic risk 2, 3

Timing Matters

At age 45, this patient is an ideal candidate for hormone therapy initiation. The benefit-risk ratio is most favorable when:

• Age <60 years, AND
• Within 10 years of menopause onset 4, 3, 5

This "timing hypothesis" is critical—starting hormone therapy in this window provides cardiovascular and mortality benefits that are lost when initiated later 3.

Absolute Contraindications to Screen For

Before prescribing, you must exclude these FDA contraindications 1:

1. Current, past, or suspected breast cancer
2. Known or suspected estrogen-sensitive malignancies
3. Undiagnosed genital bleeding (must evaluate first)
4. Untreated endometrial hyperplasia
5. Previous or current venous thromboembolism (DVT, PE)
6. Active or recent arterial thromboembolic disease (angina, MI)
7. Untreated hypertension
8. Active liver disease
9. Known hypersensitivity to hormone therapy components
10. Porphyria cutanea tarda

Additional Risk Assessment Required

Beyond absolute contraindications, assess 1, 3:

• Cardiovascular risk factors: Lipid profile, diabetes history, smoking status, family history
• Thrombophilic disorders: Factor V Leiden, prothrombin mutations
• Breast cancer risk: Family history, personal risk factors
• Smoking status: Smoking increases cardiovascular and VTE risk with estrogen 1

Clinical Decision Algorithm

Step 1: Confirm postmenopausal status and symptom severity (moderate-to-severe vasomotor symptoms)

Step 2: Verify intact uterus status → EPT required (not estrogen alone)

Step 3: Screen for absolute contraindications listed above

• If ANY present → Do not prescribe hormone therapy; consider nonhormonal alternatives 5

Step 4: Assess cardiovascular risk

• Low risk + age <60 or <10 years from menopause → EPT is appropriate 3, 5
• Moderate risk → Prefer transdermal estradiol with micronized progesterone 5
• High cardiovascular risk → Avoid hormone therapy; use nonhormonal options 5

Step 5: If antiphospholipid antibodies (aPL) positive or history of APS → Strongly contraindicated 4

Important Caveats and Pitfalls

The Progestogen Issue

Never prescribe estrogen alone to a woman with an intact uterus 1. This is non-negotiable due to endometrial cancer risk. Progestogen must be given for at least 10-14 days monthly or continuously 2.

Breast Cancer Risk Varies by Regimen

• Estrogen plus progestogen (EPT): Probably increases breast cancer risk (RR 1.27) 1, 6
• Estrogen alone: Probably makes little to no difference in breast cancer risk 6
• Risk appears to increase with longer duration of combined therapy 1

Route Matters for Thrombotic Risk

Oral estrogen increases VTE risk approximately 2-fold, while transdermal estrogen does not appear to increase VTE risk 4, 3. For women with elevated thrombotic risk factors (obesity, thrombophilic mutations), transdermal is strongly preferred 4, 2.

Duration and Monitoring

• Use the lowest effective dose for the shortest duration needed to control symptoms 1, 2, 7
• Reassess annually whether continuation is appropriate 5
• Monitor for unscheduled bleeding (requires evaluation for endometrial pathology) 5
• Ensure age-appropriate breast cancer screening 5

Age-Specific Stroke Risk

In women ≥60 years or >10 years past menopause, oral estrogen-containing therapy increases stroke risk and must be weighed carefully against benefits 3. However, at age 45, this patient is well within the safe window.

What NOT to Do

• Do not use custom-compounded "bioidentical" hormones—use FDA-approved preparations only 5
• Do not prescribe for cardiovascular disease prevention—this is not an indication 1
• Do not prescribe for dementia prevention—hormone therapy is not recommended for this purpose 1
• Do not continue indefinitely without reassessment—annual review is mandatory 5